Recite me link

1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma)? Of these patients, how many are locally advanced, recurrent and/or metastatic?
a. Total squamous cell carcinoma
b. Locally advanced
c. Recurrent and/or metastatic
2. For the metastatic head and neck cancer patients treated in the past 3 months, could you specify (if possible) how many received first-line treatment versus second-line treatment?
3. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
4. Within your health trust, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Sunitinib
b. Avelumab + Axitinib
c. Axinitib
d. Cabozantinib
e. Everolimus
f. Lenvantinib + Everolimus
g. Nivolumab
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab + Axitinib
k. Sunitinib
l. Temsirolimus
m. Tivozanib
n. Other
5. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
6. Does your trust participate in any ongoing clinical trials for the treatment of renal cell carcinoma? If so, can you please provide the name of each trial along with the number of patients taking part?

Download response Head and neck cancer (squamous cell carcinoma). 301120